Immunotherapy-Chemo Combo Based on Work of Roswell Park's Dr. Ben Seon Gets FDA Approval
June 19, 2019
June 19, 2019
BUFFALO, New York, June 19 -- The Roswell Park Cancer Institute issued the following news release:
* * *
Amherst, N.Y., researcher discovered antibody that was central to newly approved treatment for lymphoma
* * *
A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma. On June 1 . . .
* * *
Amherst, N.Y., researcher discovered antibody that was central to newly approved treatment for lymphoma
* * *
A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma. On June 1 . . .